Clinical trials: Hepatomegaly
Developmental Delay, Skeletal Abnormalities
Biomarker for Sly Disease (MPS VII) (BioSly)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Sly disease from blood (plasma)
- Conditions
- Developmental Delay, Skeletal Abnormalities, Hepatomegaly, Splenomegaly
- Trial name
- BioSly (NCT02298699)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
HCC
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
This study is a prospective phase II, single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE)…
- Trial name
- NCT04988945
- Testing
- TACE, SBRT, Durvalumab
- Where
- 2 sites in Hong Kong
- Volunteers
- 33 people
- Sponsor
- The University of Hong Kong
Hepatomegaly
Prevalence of Hepatomegaly in Children and Adolescents With Type 1 Diabetes Mellitus
To assess the prevalence of hepatomegaly in children and adolescents with type 1 diabetes mellitus, and to find out it᾿s underlying etiology.
- Trial name
- NCT03666117
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- HEPACT (NCT07068191)
- Testing
- Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Phenomen Pharma
Polycystic Liver Disease, Hepatomegaly
Open-Label Extension of LOCKCYST Trial
Positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%.
- Conditions
- Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Polycystic Kidney
- Trial name
- LOCKCYST-ext (NCT00771888)
- Testing
- lanreotide
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 54 people
- Sponsor
- Radboud University Medical Center
Hepatocellular Carcinoma
PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer
This is a multicenter, randomized, positive parallel controlled clinical study to evaluate the short-term and long-term efficacy and safety of PVL/PVE combined with DEB-TACE in the treatment of unresectable patients with large or…
- Trial name
- CCGLC-004 (NCT05103007)
- Testing
- DEB-TACE, PVL/PVE+DEB-TACE
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tongji Hospital
Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
This phase II trial studies how well nivolumab works in treating patients with primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.
- Conditions
- Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
- Trial name
- NCT02421354
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.
- Conditions
- BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Peripheral Blood White Cells
- Trial name
- NCT03801434
- Testing
- Ruxolitinib
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Stanford University
Gaucher Disease
Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease
This is an open-label expanded access trial of prGCD in patients with Gaucher disease who require enzyme replacement therapy (ERT) and who have been treated with imiglucerase but for whom the dose has been reduced or discontinued…
- Trial name
- NCT00962260
- Testing
- Plant cell expressed recombinant glucocerebrosidase (prGCD)
- Where
- 15 sites in United States, Israel
- Sponsor
- Pfizer
Farber's Lipogranulomatosis, Ceramidase Deficiency
Biomarker for Farber Disease (BioFarber)
Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood
- Conditions
- Farber's Lipogranulomatosis, Ceramidase Deficiency, Hepatomegaly, Splenomegaly
- Trial name
- BioFarber (NCT02298634)
- Where
- 3 sites in Egypt, Germany and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Amorphous, Eosinophilic, and Acellular Deposit, Constipation
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment.
- Conditions
- Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety
- Trial name
- NCT03499808
- Testing
- Isatuximab, Laboratory Biomarker Analysis
- Where
- 345 sites in United States
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Splenomegaly, Hepatomegaly
Biomarker for Gaucher Disease: BioGaucher (BioGaucher)
Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Gaucher Disease from blood (plasma)
- Trial name
- BioGaucher (NCT01331642)
- Where
- 4 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease
Octreotide in Severe Polycystic Liver Disease
This study will evaluate the effect of Octreotide LAR® on the liver volumes of patients with severe polycystic liver disease who are not candidates or decline surgical treatments such as liver cyst fenestration, liver resection…
- Conditions
- Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases
- Trial name
- NCT00426153
- Testing
- Octreotide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Polycystic Liver Disease, Hepatomegaly
Lanreotide as Treatment of Polycystic Livers
To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed.
- Conditions
- Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Polycystic Kidney, Autosomal Dominant
- Trial name
- LOCKCYST (NCT00565097)
- Testing
- Lanreotide
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 38 people
- Sponsor
- Radboud University Medical Center